Independent regulatory navigation, supplier diligence, and procurement intelligence for the four segments of US clinical decision-makers buying or recommending peptides: compounding pharmacies, telehealth platforms, peptide therapy and longevity practices, and dermatology and med spa offices.
FDA Import Alerts 66-80 and 66-41, Category 1 vs Category 2 status under 503A, the March 2026 HHS reclassification, and EU Written Confirmations as third party signal.
Read the analysis →A repeatable filter for evaluating Chinese GMP API producers: certification, FDA inspection history, Import Alert standing, EU and PMDA cross validation, operational opacity.
Read the framework →FOB China benchmarks across the GLP-1 class, Category 1 restoration peptides, and longevity targets. Aggregate ranges, not individual quotes.
Read the benchmarks →Red flag patterns, COA fraud detection, lot traceability failures, and the operational signals that separate diligent suppliers from the rest.
Read the red flags →Procurement realities differ across compounding pharmacies, telehealth platforms, peptide therapy practices, and med spa offices. Each segment gets its own content path. The regulatory tracker, supplier diligence framework, and editorial standards are shared across the publication.
FDA Import Alert standing, Category 1/2 status, COA verification, supplier diligence at scale. The segment buying API directly from manufacturers.
View pharmacy path →Vetting 503A and 503B partners at scale. Regulatory exposure mapping, compounding agreement structure, multi-state license tracking.
View telehealth path →Longevity clinics, hormone optimization, peptide therapy. Pharmacy quality matters more here than anywhere else. How to vet, switch, and maintain consistency.
View provider path →Smaller scale, higher per-patient context. Choosing the right compounding pharmacy partner, integrating peptides into existing protocols.
View med spa path →Everything you need to know about evaluating GMP-certified peptide suppliers, from documentation to facility audits.
503A vs 503B, Category 1/2 classifications, FDA requirements, and state-by-state variance analysis.
How to read, verify, and validate Certificates of Analysis. HPLC, LC-MS, and endotoxin testing explained.
Complete buyer's guide: pricing benchmarks, supplier evaluation frameworks, import logistics, and RFQ best practices.
Evidence-based guide to longevity and anti-aging peptides: research status, sourcing, and quality verification.
Free 38-page playbook on regulatory navigation, supplier diligence, and the 12-point red flag checklist for licensed peptide procurement teams.
Industry analysis, sourcing intelligence, and regulatory updates.
Learn to identify fraudulent Certificates of Analysis in under a minute. Common red flags, what legitimate COAs look like, and verification steps.
Clear breakdown of 503A traditional compounding vs 503B outsourcing facility regulations and what the 2026 Category 1 changes mean for peptide buyers.
The FDA's Category 1 vs Category 2 peptide classification determines what compounding pharmacies can prepare. Here's what changed in 2026 and what it means.
Understand the difference between HPLC and LC-MS testing methods for peptide purity, when each matters, and what to look for on a COA.
Five warning signs that indicate a peptide supplier may not be trustworthy. Protect your supply chain with this evaluation framework.
Complete compliance checklist for importing peptide APIs into the United States. FDA requirements, customs documentation, and common pitfalls.
Why South Korea is emerging as a strategic peptide API sourcing hub. MFDS regulatory standards, key manufacturers, and procurement advantages.
Complete procurement workflow for compounding pharmacies sourcing peptide APIs.
Free 38-page playbook on regulatory navigation, supplier diligence, and the 12-point red flag checklist. For licensed procurement decision makers only.
Get the Buyer’s Guide →